Related Experiment Video
Updated: Jan 14, 2026
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
Published on: September 22, 2023
Prevention of damage induced by aspirin in the GI tract
1Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA. jscheima@umich.edu
Insights
Low-dose aspirin use for cardiovascular disease can cause gastrointestinal bleeding. Proton pump inhibitors are the most effective strategy to prevent upper GI side effects, but small bowel injury remains a concern.
Area of Science:
- Gastroenterology
- Cardiology
- Pharmacology
Background:
- Low-dose aspirin is widely prescribed for cardiovascular disease management.
- Aspirin, while safer than NSAIDs, poses risks of acute and chronic GI bleeding.
- Gastrointestinal (GI) toxicity from aspirin is a significant healthcare issue.
Purpose of the Study:
- To review strategies for minimizing upper GI side effects of aspirin.
- To evaluate the efficacy of different agents in preventing aspirin-induced GI toxicity.
- To discuss the risks of small bowel injury associated with aspirin use.
Main Methods:
- Review of current literature on aspirin toxicity and prevention strategies.
- Comparison of the effectiveness of prostaglandin analogues, H2 receptor antagonists, and proton pump inhibitors (PPIs).
- Assessment of alternative antiplatelet agents and their GI safety profiles.
Main Results:
- Proton pump inhibitors (PPIs) are the most effective strategy for preventing upper GI side effects of aspirin, offering convenience and fewer side effects.
- Substituting clopidogrel for aspirin does not appear to reduce GI risk.
- Small bowel injury from aspirin can be detected by capsule endoscopy, but no preventive strategies are established.
Conclusions:
- PPIs are recommended for mitigating upper GI risks associated with low-dose aspirin therapy.
- Current strategies do not address aspirin-induced small bowel injury.
- Further research is needed to develop methods for preventing small bowel toxicity from aspirin.
Abstract:
Low-dose aspirin (325 mg or less) alone and in combination with other antiplatelet agents is widely used for the management of cardiovascular disease. Although the risk with low-dose aspirin alone is less than Nonsteroidal anti-inflammatory drugs (NSAIDs), given widespread use, aspirin related toxicity has become a substantial health care problem due to acute and chronic GI bleeding. A variety of strategies are currently available to minimize the risk of developing upper GI side effects of aspirin. Agents that have efficacy include oral prostaglandin analogues, H2 receptor antagonists and proton pump inhibitors. PPIs appear to be the most effective strategy, with the least side effects and the convenience of once daily dosing. The substitution of another antiplatelet agent such as clopidogrel for aspirin alone does not appear to provide a safer alternative to low-dose aspirin for patients at GI risk. Small bowel injury can occur with aspirin and can be assessed with capsule endoscopy; however, no strategy is known to reduce this potential toxicity in clinical practice.
More Related Videos
08:56Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:14Prevention of Further Absorption of Poison